ChemIDplus Advanced United States National Library of Medicine Accessed on 29 Jul 2013 from http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp. Note: Compound name must be entered under "Substance Identification" and then "Names and Synonyms" selected to view synonyms.
Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis. Patti F, Lo Fermo S Autoimmune Dis. 2011; 2011:961702. Epub 2011 Mar 15. PMID: 21547093. Abstract
Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Weiner HL, Cohen JA Mult Scler. 2002 Apr; 8(2):142-54. PMID: 11990872. Abstract
Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks. Rinaldi L, Perini P, Calabrese M, Gallo P Neurol Sci. 2009 Oct; 30 Suppl 2:S171-3. PMID: 19882369. Abstract
Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance. Harrison DM, Gladstone DE, Hammond E, Cheng J, Jones RJ, Brodsky RA, Kerr D, McArthur JC, Kaplin A Mult Scler. 2012 Feb; 18(2):202-9. Epub 2011 Aug 24. PMID: 21865410. Abstract
Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Kastan MB, Schlaffer E, Russo JE, Colvin OM, Civin CI, Hilton J Blood. 1990 May 15; 75(10):1947-50. PMID: 2337669. Abstract
High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases. DeZern AE, Petri M, Drachman DB, Kerr D, Hammond ER, Kowalski J, Tsai H-L, Loeb DM, Anhalt G, Wigley F, et al. Medicine (Baltimore). 2011 Mar; 90(2):89-98. PMID: 21358440. Abstract
Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. Likosky WH, Fireman B, Elmore R, Eno G, Gale K, Goode GB, Ikeda K, Laster J, Mosher C, Rozance J J Neurol Neurosurg Psychiatry. 1991 Dec; 54(12):1055-60. PMID: 1783915. Abstract
Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. Gobbini MI, Smith ME, Richert ND, Frank JA, McFarland HF J Neuroimmunol. 1999 Sep 1; 99(1):142-9. PMID: 10496187. Abstract
Accentia Biopharmaceuticals Announces that Revimmune Autoimmune Disease Therapy is Featured in Peer-review Journal Drugs.com, 4 May 2011 Accessed on 12 Mar from http://www.drugs.com/clinical_trials/accentia-biopharmaceuticals-announces-revimmune-autoimmune-therapy-featured-peer-review-journal-11664.html.
Cyclophosphamide National Cancer Institute, 16 Oct 2011 Accessed on 12 Mar 2012 from http://www.cancer.gov/cancertopics/druginfo/cyclophosphamide.
Drugs to be Discontinued FDA, 6 Jan 2012 Accessed on 12 Mar 2012 from http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050794.htm.
Evaluation of the immunosuppressive effects of cyclophosphamide in patients with multiple sclerosis. ten Berge RJ, van Walbeek HK, Schellekens PT Clin Exp Immunol. 1982 Dec; 50(3):495-502. PMID: 7165996. Abstract
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations FDA, Jan 2012 Accessed on 12 Mar 2012 from http://www.accessdata.fda.gov/scripts/cder/ob/docs/tempai.cfm. Note that compound name must be entered under “Search by Active Ingredient."
Administration of monthly-pulse cyclophosphamide in multiple sclerosis patients. Effects of long-term treatment on immunologic parameters. Moody DJ, Kagan J, Liao D, Ellison GW, Myers LW J Neuroimmunol. 1987 Mar; 14(2):161-73. PMID: 3818941. Abstract
Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Smith DR, Balashov KE, Hafler DA, Khoury SJ, Weiner HL Ann Neurol. 1997 Sep; 42(3):313-8. PMID: 9307252. Abstract
Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. Comabella M, Balashov K, Issazadeh S, Smith D, Weiner HL, Khoury SJ J Clin Invest. 1998 Aug 15; 102(4):671-8. PMID: 9710434. Abstract
[Immunodepressive therapy in neurology]. Girard PF, Aimard G, Pellet H Presse Med. 1967 Apr 22; 75(19):967-8. PMID: 6025851. Abstract
Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years. Gonsette RE, Demonty L, Delmotte P J Neurol. 1977 Feb 17; 214(3):173-81. PMID: 65452. Abstract
Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Carter JL, Hafler DA, Dawson DM, Orav J, Weiner HL Neurology. 1988 Jul; 38(7 Suppl 2):9-14. PMID: 2838768. Abstract
Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, LaPierre Y, Herndon R, Lehrich JR, Hauser SL, Turel A Neurology. 1993 May; 43(5):910-8. PMID: 8388090. Abstract
A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Smith DR, Weinstock-Guttman B, Cohen JA, Wei X, Gutmann C, Bakshi R, Olek M, Stone L, Greenberg S, Stuart D, et al. Mult Scler. 2005 Oct; 11(5):573-82. PMID: 16193896. Abstract
Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis (PROMESS) ClinicalTrials.gov, 12 Oct 2010 Accessed on 10 Mar 2012 from http://clinicaltrials.gov/ct2/show/NCT00241254.
The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. Lancet. 1991 Feb 23; 337(8739):441-6. PMID: 1671468. Abstract
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, Mills JA, Weiner HL N Engl J Med. 1983 Jan 27; 308(4):173-80. PMID: 6294517. Abstract
The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis. Lamers KJ, Uitdehaag BM, Hommes OR, Doesburg W, Wevers RA, von Geel WJ J Neurol Neurosurg Psychiatry. 1988 Oct; 51(10):1334-7. PMID: 2465387. Abstract
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Krishnan C, Kaplin AI, Brodsky RA, Drachman DB, Jones RJ, Pham DL, Richert ND, Pardo CA, Yousem DM, Hammond E, et al. Arch Neurol. 2008 Aug; 65(8):1044-51. Epub 2008 Jun 09. PMID: 18541787. Abstract
The history of the oxazaphosphorine cytostatics. Brock N Cancer. 1996 Aug 1; 78(3):542-7. PMID: 8697402. Abstract
Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells. Crook TR, Souhami RL, McLean AE Cancer Res. 1986 Oct; 46(10):5029-34. PMID: 3463409. Abstract
High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation. McGuire TR, Gwilt P, Manouvilov K, Healey K, Ursick MM, Nash RA, Pavletic SZ Int Immunopharmacol. 2003 Feb; 3(2):279-83. PMID: 12586609. Abstract
Cyclophosphamide for multiple sclerosis. La Mantia L, Milanese C, Mascoli N, D'Amico R, Weinstock-Guttman B Cochrane Database Syst Rev. 2007(1):CD002819. PMID: 17253481. Abstract
Revimmune (High-Dose Cyclophosphamide) for Autoimmune Diseases Accentia Biopharmaceuticals Accessed on 11 May 2012 from http://www.accentia.net/science_revimmune.php.
Accentia Biopharmaceuticals Conducts Investigator Meeting in Preparation for New Multiple Sclerosis Drug Study for Cyrevia™ Businesswire.com, 04 May 2012 Accessed on 11 May 2012 from http://www.businesswire.com/news/home/20120504005213/en/Accentia-Biopharmaceuticals-Conducts-Investigator-Meeting-Preparation-Multiple.
Physicians from Accentia and Johns Hopkins University present plans for new MS drug study for Cyrevia PHARMABIZ.com, 7 May 2012 Accessed on 16 May 2012 from http://pharmabiz.com/NewsDetails.aspx?aid=68863&sid=2.
Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. Patti F, Reggio E, Palermo F, Fiorilla T, Politi G, Nicoletti A, Reggio A J Neurol. 2004 Dec; 251(12):1502-6. PMID: 15645351. Abstract
High-dose cyclophosphamide in the treatment of multiple sclerosis. Schwartzman R J, Simpkins N, Alexander GM, Reichenberger E, Ward K, Lindenberg N, Topolsky D, Crilley P CNS Neurosci Ther. 2009 Summer; 15(2):118-27. Epub 2009 Feb 23. PMID: 19243391. Abstract
Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis. Perini P, Gallo P J Neurol. 2003 Jul; 250(7):834-8. PMID: 12883926. Abstract
Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort. Portaccio E, Zipoli V, Siracusa G, Piacentini S, Sorbi S, Amato MP Mult Scler. 2003 Oct; 9(5):446-50. PMID: 14582767. Abstract
No increase in cancer incidence detected after cyclophosphamide in a French cohort of patients with progressive multiple sclerosis. Le Bouc R, Zéphir H, Majed B, Vérier A, Marcel M, Vermersch P Mult Scler. 2012 Jan; 18(1):55-63. Epub 2011 Aug 15. PMID: 21844065. Abstract
Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. Zipoli V, Portaccio E, Hakiki B, Siracusa G, Sorbi S, Amato M P J Neurol Sci. 2008 Mar 15; 266(1-2):25-30. Epub 2007 Sep 17. PMID: 17870094. Abstract
Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis. Karni A, Balashov K, Hancock WW, Bharanidharan P, Abraham M, Khoury SJ, Weiner HL J Neuroimmunol. 2004 Jan; 146(1-2):189-98. PMID: 14698862. Abstract
Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms. Awad A, Stüve O Ther Adv Neurol Disord. 2009 Nov; 2(6):50-61. PMID: 21180630. Abstract
The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up. Reggio E, Nicoletti A, Fiorilla T, Politi G, Reggio A, Patti F J Neurol. 2005 Oct; 252(10):1255-61. Epub 2005 Jun 06. PMID: 15940386. Abstract
Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. Patti F, Cataldi ML, Nicoletti F, Reggio E, Nicoletti A, Reggio A J Neurol Neurosurg Psychiatry. 2001 Sep; 71(3):404-7. PMID: 11511721. Abstract
Cyclophosphamide therapy in pediatric multiple sclerosis. Makhani N, Gorman MP, Branson HM, Stazzone L, Banwell BL, Chitnis T Neurology. 2009 Jun 16; 72(24):2076-82. Epub 2009 May 13. PMID: 19439723. Abstract
Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. Hommes OR, Prick JJ, Lamers KJ Clin Neurol Neurosurg. 1975; 78(1):59-72. PMID: 1157430. Abstract
Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Hohol MJ, Olek MJ, Orav EJ, Stazzone L, Hafler DA, Khoury SJ, Dawson DM, Weiner HL Mult Scler. 1999 Dec; 5(6):403-9. PMID: 10618696. Abstract
Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Khan OA, Zvartau-Hind M, Caon C, Din MU, Cochran M, Lisak D, Tselis AC, Kamholz JA, Garbern JY, Lisak RP Mult Scler. 2001 Jun; 7(3):185-8. PMID: 11475443. Abstract
Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. Zephir H, de Seze J, Duhamel A, Debouverie M, Hautecoeur P, Lebrun C, Malikova I, Pelletier J, Sénéchal O, Vermersch P J Neurol Sci. 2004 Mar 15; 218(1-2):73-7. PMID: 14759636. Abstract
Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study. La Mantia L, Eoli M, Salmaggi A, Torri V, Milanese C Ital J Neurol Sci. 1998 Feb; 19(1):32-6. PMID: 10935857. Abstract
High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Gladstone DE, Zamkoff KW, Krupp L, Peyster R, Sibony P, Christodoulou C, Locher E, Coyle PK Arch Neurol. 2006 Oct; 63(10):1388-93. Epub 2006 Aug 14. PMID: 16908728. Abstract
High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients. Gladstone DE, Golightly MG, Brannagan TH J Neuroimmunol. 2007 Oct; 190(1-2):121-6. Epub 2007 Sep 14. PMID: 17854912. Abstract
Repeated treatment with high dose cyclophosphamide for severe autoimmune diseases. DeZern AE, Styler MJ, Drachman DB, Hummers LK, Jones RJ, Brodsky RA Am J Blood Res. 2013; 3(1):84-90. Epub 2013 Jan 17. PMID: 23358715. Abstract
[Cyclophosphamide pulse therapy effective for childhood-onset refractory multiple sclerosis: a case report]. Ikeda T, Kagitani-Shimono K, Iwatani Y, Kitai Y, Tachibana M, Tominaga K, Okinaga T, Nagai T, Ozono K No To Hattatsu. 2013 Jan; 45(1):49-52. PMID: 23593746. Abstract
Cyclophosphamide so-so verdict in progressive MS Susman E, MedPage Today, 4 Oct 2013 Accessed on 8 Oct 2013 from http://www.medpagetoday.com/MeetingCoverage/ECTRIMS/42065.
Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Yaguchi H, Sakushima K, Takahashi I, Nishimura H, Yashima-Yamada M, Nakamura M, Tsuzaka K, Maruo Y, Takahashi T, Yabe I, et al. Intern Med. 2013; 52(9):969-72. Epub 2012 Mar 01. PMID: 23648715. Abstract
Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide. Patti F, Messina S, D'Amico E, Lo Fermo S, Zappia M Acta Neurol Scand. 2014 Apr 15. PMID: 24730672. Abstract
Disease-modifying therapies in Chinese children with multiple sclerosis. Yang F, Huang HD, Yang Y, Wu W Turk J Pediatr. 2014 Sep-Oct; 56(5):482-6. PMID: 26022582. Abstract